Efficacy of short-course antibiotic regimens for community-acquired pneumonia: A meta-analysis

被引:136
作者
Li, Jonathan Z.
Winston, Lisa G.
Moore, Dan H.
Bent, Stephen
机构
[1] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, San Francisco VA Med Ctr, Infect Dis Sect, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA
关键词
antibiotics; community-acquired pneumonia; pneumonia; short-course;
D O I
10.1016/j.amjmed.2007.04.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: There is little consensus on the most appropriate duration of antibiotic treatment for community-acquired pneumonia. The goal of this study is to systematically review randomized controlled trials comparing short-course and extended-course antibiotic regimens for community-acquired pneumonia. METHODS: We searched MEDLINE, Embase, and CENTRAL, and reviewed reference lists from 1980 through June 2006. Studies were included if they were randomized controlled trials that compared short-course (7 days or less) versus extended-course (> 7 days) antibiotic monotherapy for community-acquired pneumonia in adults. The primary outcome measure was failure to achieve clinical improvement. RESULTS: We found 15 randomized controlled trials matching our inclusion and exclusion criteria comprising 2796 total subjects. Short-course regimens primarily studied the use of azithromycin (n = 10), but trials examining beta-lactams (n = 2), fluoroquinolones (n = 2), and ketolides (n = 1) were found as well. Of the extended-course regimens, 3 studies utilized the same antibiotic, whereas 9 involved an antibiotic of the same class. Overall, there was no difference in the risk of clinical failure between the short-course and extended-course regimens (0.89, 95% confidence interval [CI], 0.78-1.02). In addition, there were no differences in the risk of mortality (0.81, 95% CI, 0.46-1.43) or bacteriologic eradication (1.11, 95% CI, 0.76-1.62). In subgroup analyses, there was a trend toward favorable clinical efficacy for the short-course regimens in all antibiotic classes (range of relative risk, 0.88-0.94). CONCLUSIONS: The available studies suggest that adults with mild to moderate community-acquired pneumonia can be safely and effectively treated with an antibiotic regimen of 7 days or less. Reduction in patient exposure to antibiotics may limit the increasing rates of antimicrobial drug resistance, decrease cost, and improve patient adherence and tolerability. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:783 / 790
页数:8
相关论文
共 59 条
[1]  
[Anonymous], JPN J CHEMOTHER
[2]  
Awasthi S, 2004, BMJ-BRIT MED J, V328, P791
[3]   LENGTH OF ANTIBIOTIC-THERAPY IN IN-PATIENTS WITH PRIMARY PNEUMONIAS [J].
AWUNORRENNER, C .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1979, 73 (03) :235-240
[4]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[5]  
BJERRE LM, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002109
[6]   EFFICACY AND SAFETY OF AZITHROMYCIN VERSUS BENZYLPENICILLIN OR ERYTHROMYCIN IN COMMUNITY-ACQUIRED PNEUMONIA [J].
BOHTE, R ;
VANTWOUT, JW ;
LOBATTO, S ;
ALBLAS, ABV ;
BOEKHOUT, M ;
NAUTA, EH ;
HERMANS, J ;
VANDENBROEK, PJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (03) :182-187
[7]  
BRION JP, 1990, PATHOL BIOL, V38, P521
[8]   Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial [J].
Chastre, J ;
Wolff, M ;
Fagon, JY ;
Chevret, S ;
Thomas, F ;
Wermert, D ;
Clementi, E ;
Gonzalez, J ;
Jusserand, D ;
Asfar, P ;
Perrin, D ;
Fieux, F ;
Aubas, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (19) :2588-2598
[9]   Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review [J].
Clay, KD ;
Hanson, JS ;
Pope, SD ;
Rissmiller, RW ;
Purclum, PP ;
Banks, PM .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :415-420
[10]  
Contopoulos-Ioannidis DG, 2001, J ANTIMICROB CHEMOTH, V48, P691, DOI 10.1093/jac/48.5.691